openPR Logo
Press release

Evonik and BellaSeno partner to enable the launch of an innovative 3D printed breast implant technology

11-12-2019 01:59 PM CET | Health & Medicine

Press release from: BellaSeno GmbH

/ PR Agency: akampion
- 3D printed breast scaffolds to be made of RESOMER®
- Degradation of RESOMER® to match the growth of the patient’s own tissue for natural breasts
- Technology designed to improve quality of life for patients after breast reconstruction and augmentation
- Human clinical trials to commence later this year

Evonik, a global leader in biomaterials for implantable medical devices, and BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, today announced the signing of a long-term agreement for the use of a RESOMER® bioresorbable polymer for an innovative breast implant technology.

BellaSeno will use RESOMER® in its Senella® breast scaffold products with a proprietary additive manufacturing process. Designed to be implanted after breast reconstruction, augmentation or revision surgery, the RESOMER® polymer features mechanical properties and a degradation profile that allow the scaffold to safely absorb at a rate that matches the formation of the patient’s own tissue. Scaffolds will be available in different sizes and shapes to match the patients’ needs.

In addition to enabling the formation of natural breast tissue, the process avoids the use of silicone implants which are associated with clinical risks such as capsular contracture and device complications such as rupture and deflation.

First-in-human clinical trials of the Senella® scaffolds with RESOMER® are scheduled to commence in Germany this quarter. Under the agreement, Evonik will supply its RESOMER® polymer for clinical and commercial use.

“Evonik is pleased to be partnering with BellaSeno in the clinical development and commercialization of their innovative, 3D printed breast implant technology,” said Dr. Jean-Luc Herbeaux, SVP and General Manager of the Health Care business line. “Senella® breast implant scaffolds can potentially enhance the quality of life of millions of patients worldwide who undertake surgical procedures each year. This agreement underlines the ability of Evonik to leverage the safety and versatility of RESOMER® polymers, together with our advanced application technology services, to support customers in the commercialization of innovative medical devices.”

“BellaSeno GmbH is very excited to be working together with Evonik in this collaboration,” said Dr. Simon Champ, Co-Founder and Chief Executive Officer of BellaSeno. “The level of support provided by Evonik has been excellent.”

The Health Care business line, which is part of the Nutrition & Care segment of Evonik, serves more than 1,000 pharmaceutical, nutraceutical and medical device customers worldwide. Its portfolio of RESOMER® bioresorbable polymers, Endexo® surface modification technologies and application technologies services is a core element of the Health & Care growth engine, which helps drive Evonik’s profitable and balanced growth.

###

BellaSeno Contact person
Dr. Simon Champ
Deutscher Platz 5a (BioCity)
04103 Leipzig
Germany
simon.champ@bellaseno.com
Tel.: +49 176 8033 7273

BellaSeno press contact
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Evonik Contact person
Dr. Jürgen Krauter
Head of Communications
Nutrition & Care
Phone +49 6181 59-6847
Fax +49 6181 59-76847
juergen.krauter@evonik.com

Evonik Contact person
specialized press
Stephen Allan
External Communications – Health Care
Phone + 49 6151 18-3508
stephen.allan@evonik.com

Evonik Contact U.S. press
Robert Brown
Phone +1 973 906-4635
robert.brown@evonik.com

About Evonik
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations

About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around
€4.6 billion in 2018.

Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

About BellaSeno
BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig, Germany. The Company is developing novel absorbable breast implants made by additive manufacturing (3D-printing). The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE). The company is thereby co-funded from tax resources based on the budget adopted by the members of Saxon State Parliament.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Evonik and BellaSeno partner to enable the launch of an innovative 3D printed breast implant technology here

News-ID: 1865562 • Views: 443

More Releases from BellaSeno GmbH

BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regener …
- Collaboration with Fraunhofer IZI further expanded - Funding provided by Sächsische Aufbaubank Leipzig, Germany, July 1, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in close collaboration with Fraunhofer Institute for Cell Therapy and Immunology
BellaSeno Wins Prestigious German Innovation Award 2021
- Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies Leipzig, Germany, May 18, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business - Medical Technologies. BellaSeno has been chosen among
BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facil …
- Seamless transition from R&D to commercial-scale additive manufacturing - Leading-edge cleanroom, no-touch manufacturing - GMP capabilities for internal and contract manufacturing Leipzig, Germany, November 17, 2020 - BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany. It is the one
BellaSeno and Charite - Universitaetsmedizin Berlin Collaborate Under BMBF-Funde …
- Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes - BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485 Leipzig, Germany, March 24, 2020 - BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charite - Universitaetsmedizin Berlin under the recently established SyMBoD consortium. Under the agreement, BellaSeno will design and manufacture personalized, 3D-printed, absorbable

All 5 Releases


More Releases for Evonik

Algal DHA Oil Market Outlook by Trend, Regional Demand, Product, and Forecast Re …
LOS ANGELES, United States: The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Algal DHA Oil market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Algal DHA Oil market. The authors of the report have segmented the global Algal DHA Oil
Polyimide Fiber Market Key Trends | Aoshen, HiPolyking, Evonik
Global Polyimide Fiber Market: Overview The global market for polyimide fibers will likely tread a moderate yet steady growth trajectory over the course of the next few years on account of the complicated manufacturing process and the subsequent high price of the fibers. Hence such fibers are used mostly in a few areas. Owing to costly and complex manufacturing procedure, there are a limited number of manufacturers operating in the market
Defoamers Market 2018 Top Key Vendors: BASF, Dow, Ashland, Evonik Industries, Cl …
Defoamers Market will likely surpass USD 4.3 billion by 2024 according to this new research report. Rising use of surface active agents in pulp & paper production will likely showcase positive impressions on the defoamers market globally. The pulp & paper industry will grow at a substantial rate in the forecast period with a CAGR of nearly 4.5%. China leads the pulp & paper market in terms of production quantity and
Global Surfactant Market Segmentation By Type Analysis 2018-2025: Competitor Lik …
databridgemarketrearch.Com Adds “Global Surfactant Market- Industry Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025” To Its Study Directory. The report covers the present scenario and the growth prospects of the global surfactant for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth
Global BCAA Consumption Market 2018 - Ajinomoto, Kyowa, Evonik
Apex Market Reports, recently published a detailed market research study focused on the "BCAA Consumption Market" across the global, regional and country level. The report provides 360° analysis of "BCAA Consumption Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global BCAA Consumption industry, and estimates the future trend of BCAA Consumption market
Global Sulfamide Market 2017-ARKEMA, Flexsys and EVONIK
Global Sulfamide Market Report illustrates the present development status of Sulfamide along with the growth of Sulfamide expected during the forecast period during 2017-2022. Sulfamide Market analyses the industry based on different factors like growth trends, consumer volume, Sulfamide market size and demand and supply status. Sulfamide Market is a beneficial research material which conducts a competitive analysis of the Sulfamide market. This report also portrays the Sulfamide industry structure